Nanjing University School Of Medicine

This study compares two newer biologic drugs (belimumab and telitacicept) against the current standard treatment for lupus nephritis, a serious kidney complication of lupus. Fifty patients with active kidney inflammation will receive either a biologic drug alone, standard therapy…